Background
In patients presenting with NSTE-ACS, multivessel coronary artery disease (CAD) is associated with adverse outcome.
Methods
Patients with multivessel CAD and NSTE-ACS that underwent percutaneous coronary intervention were included. The culprit lesion was defined by reviewing each patient's angiographic report, electrocardiogram, echocardiogram and, if available, nuclear stress test. All patients had at least 2 vessels with Ն50% stenosis, and the angiographic severity of CAD was assessed using the Duke Prognostic Angiographic Score. Patients with coronary bypass grafts, chronic total occlusions, and those with uncertain culprit lesions were excluded. Our end point was the composite of death, myocardial infarction, or any target vessel revascularization.
Results
From January 1995 to June 2005, 1,240 patients with ACS and multivessel CAD underwent percutaneous coronary intervention with bare-metal stenting and met our study criteria. Of these, 479 underwent multivessel and 761 underwent culprit-only stenting. There were 442 events during a median follow-up of 2.3 years. Multivessel intervention was associated with lower death, myocardial infarction, or revascularization after both adjusting for baseline and angiographic characteristics (hazard ratio 0.80; 95% confidence interval 0.64 to 0.99; p ϭ 0.04) and propensity matched analysis (hazard ratio 0.67; 95% confidence interval 0.51 to 0.88; p ϭ 0.004).
Conclusions
In patients with multivessel CAD presenting with NSTE-ACS, multivessel intervention was significantly associated with a lower revascularization rate, which translated to a lower incidence of the composite end point compared with culprit-only stenting. Coronary artery disease (CAD) is a diffuse process and, often, patients presenting with unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) have multiple lesions that may be suitable for percutaneous coronary intervention (PCI) (1) (2) (3) . In the era of contemporary medical therapy, it is not clear whether intervening on stable chronic nonculprit lesions in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) can prevent major adverse cardiovascular events. In addition, multivessel stenting in this setting could potentially be associated with greater dye load and periprocedural myocardial infarction (MI) secondary to side branch closure and distal embolization (4, 5) .
The American College of Cardiology/American Heart Association guidelines for multivessel PCI in patients presenting with NSTE-ACS recommend that "it be performed when there is a high likelihood of success and a low risk of morbidity and the vessel(s) to be dilated subtend a moderate or large area of viable myocardium and have high risk by noninvasive testing" (6) . We sought to examine the clinical outcomes in patients with multivessel CAD presenting with NSTE-ACS who had undergone multivessel versus culpritonly stenting.
Methods
Study population. The study participants are from an ongoing registry of patients undergoing PCI at the Cleveland Clinic. For the purpose of this study, we included all patients from January 1995 to June 2005 who underwent PCI with bare-metal stents. Baseline characteristics, angiographic data, medication use, and other data were prospectively obtained and recorded by trained research coordinators. Patients with chronic total occlusions, staged procedures, and those who had prior bypass graft surgery were excluded. Non-ST-segment elevation acute coronary syndromes were defined as unstable angina or NSTEMI. Unstable angina was defined as rest, new-onset, progressive, or postinfarct chest pain, and NSTEMI was defined as the occurrence of troponin elevation with electrocardiographic changes or angina. The institutional review board of the Multivessel Versus Culprit-Only Stenting in ACS for the differences in baseline demographic features, angiographic variables, treatment assignment, and other confounders. The proportional hazards assumption was confirmed by testing the weighted Schoenfeld residuals and by plotting hazard ratio against time plots for selected variables. Additionally, time-dependent analyses were performed to examine the potential effect of subsequent revascularization on later death or MI.
To minimize the impact of confounding by risk factors, we used the technique of propensity analysis. We used nonparsimonious logistic regression model to generate a propensity score for individuals who had undergone multivessel stenting. We considered all variables listed in Table 1 for this model. We then matched each subject from the multivessel stented group to an individual that had undergone culprit-only stenting using the derived propensity score. Subsequently, we performed a Cox proportional hazards modeling in which we incorporated all baseline characteristics in addition to the propensity score for the propensity-matched patients (version 9.1, SAS Institute, Cary, North Carolina).
Results
Baseline characteristics. Baseline and target lesion characteristics of patients stratified by multivessel and culpritonly coronary intervention are shown in Table 1 . In general, the 2 groups were similar regarding risk factors for CAD and medical history. Clinical outcomes. There were a total of 442 events during a median follow-up of 2.3 years (interquartile range 0.2 to 4.3 years). Although in unadjusted analysis no significant differences were noted between the 2 groups, in multivariable model after adjusting for baselines characteristics, medical history, angiographic data, Duke Prognostic Score, operator volume, and location of culprit lesion, multivessel intervention was associated with lower incidence of composite end point of death, MI, or revascularization ( Table 2 , Fig. 1A) . However, there were no differences observed for composite end point of death or MI ( Table 2 , Fig. 1B ), or death ( Table 2 , Fig. 1C) , whereas there was a trend toward lower revascularization (Table 2, Fig. 1D ). In addition, no significant differences were found in the rate of postprocedural CK increase (7.3% vs. 5.0%, p ϭ 0.09) or creatinine increase (4% vs. 3%, p ϭ 0.32) among the 2 groups. However, in a subset of patients in which fluoroscopy time was available (n ϭ 254), patients undergoing multivessel PCI had significantly higher fluoroscopy time compared with those that underwent culprit-only PCI (46 Ϯ 190 min vs. 25 Ϯ 22 min, p Ͻ 0.001). Propensity-matched analysis. To account for multiple confounding features that are associated with multivessel stenting, such as higher prevalence of proximal left anterior descending artery disease and worse Duke Prognostic Score, we generated a propensity matched cohort using all variables shown in Table 1 . After generating a propensity score (c-statistic ϭ 0.78), 315 of the 479 patients who underwent multivessel stenting were matched with a patient who underwent culprit-only stenting. There were no differences in more than 20 baseline characteristics for the propensity matched subjects. There were 222 events for a median follow-up of 2.7 years. Even after propensity-matched analysis, multivessel intervention remained associated with lower incidence of composite end point of death, MI, or revascularization in both unadjusted and multivariable adjusted analyses ( Table 2 , Fig. 2A) . However, there were no differences seen for composite end point of death or MI ( Table 2 , Fig. 2B ), death ( Table 2 , Fig. 2C) ; whereas there was a significantly lower rate of revascularization in patients undergoing multivessel intervention ( Table 2 , Fig. 2D ). In addition, no significant differences were observed between multivessel versus culprit-only stenting in the rate of postprocedural CK elevation (7% vs. 5%, p ϭ 0.31) or creatinine rise (4% vs. 3%, p ϭ 0.68).
To further examine the impact of future revascularization on mortality, we treated revascularization as a time-dependent covariate. In this analysis, future revascularization did not have an impact on mortality (adjusted hazard ratio, 1.38; 95% confidence interval 0.90 to 2.09; p ϭ 0.14).
Discussion
In a large cohort of patients with unstable angina or NSTEMI undergoing PCI, nonculprit multivessel baremetal stenting was associated with lower incidence of death, MI, or revascularization, which was mainly driven by significantly lower incidence of revascularization in the multivessel intervention group. To our knowledge, this is the largest study to examine systematically the safety and efficacy of multivessel compared with culprit-only stenting in patients with multivessel CAD presenting with NSTE-ACS while accounting for both baseline and angiographic characteristics.
In U.S. in 2001, there were more than 1.6 million patients discharged from hospital with the diagnosis of NSTE-ACS. The invasive approach is the preferred method for treating such patients (8 -10) . Although interventions to culprit lesions have clinical benefit (8 -10) , little is known about the safety and efficacy of nonculprit multivessel stenting in the setting of NSTE-ACS. Further- 
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Multivessel Versus Culprit-Only Stenting in ACS more, multivessel stenting could potentially have adverse effects secondary to increased contrast load and side branch closure, leading to renal dysfunction and periprocedural MI, respectively (4). Additionally, patients with NSTE-ACS are in a heightened thrombotic and inflammatory state and may be more prone to adverse effects of multivessel PCI (11) . Finally, multivessel disease is associated with increased in-stent restenosis, and placing multiple stents may be associated with increased revascularization secondary to in-stent restenosis (11) . The safety and efficacy of multivessel PCI was examined in a subpopulation of the TACTICS-TIMI-18 (Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction-18) trial. Of the 290 patients with multivessel disease, 224 underwent culprit lesion and 66 multivessel stenting (12) . There were no significant differences for the 6-month composite end point of death or MI. Other studies have looked at the safety and efficacy of multivessel stenting, but none have been in the setting of unstable angina or NSTEMI (13) (14) (15) (16) . Study limitations. Our study has several limitations. First, it is an observational study. Second, the mindset of the operator and the procedure progression are very important but very difficult to measure in an observational study. A potential culprit-only procedure in which the culprit goes smoothly can turn into a multivessel procedure, whereas a planned multivessel procedure that is more difficult than predicted can become a culprit only procedure. Third, individuals who underwent multivessel PCI may get more follow-up procedures as well as differential ascertainment of events. However, these differences would most likely lead to more revascularization in patients with multivessel PCI. Fourth, all patients in our study had bare-metal stents; however, these data could most likely be extrapolated to drug-eluting stents, as these devices have a significantly lower restenosis rate and have not yet been shown to decrease death or MI. Fifth, we had limited data on contrast volume and fluoroscopy time.
Conclusions
In the current study, nonculprit multivessel stenting reduced future revascularization rate but was not associated with lower death or MI. Although the current study does not support multivessel stenting to reduce mortality on angiographically significant lesions in patients with stable CAD, future technologies that allow the in vivo assessment of vulnerable plaques may at some point provide an opportunity to decrease death or
